XaTek
The First Point-of-Care Diagnostic for Hemophilia & an Emerging Class of Anti-Coagulants
doctor-1149149_1280.jpg

What We've Achieved

Our Proudest Moments

Here's just a small sampling of some of our achievements

 

Micro-sizing our device

Unique handheld design that facilitates ease of use, while enabling multiple lines of product sales that include both hardware, consumables and data mining.

 

Accredited Recognition

Already the recipient of industry accolades, having received honors at the 58th annual American Society of Hematology & Oncology (ASH) conference.

 

Our People

Seasoned management team has partnered with Nottingham Spirk to design and engineer the company’s products. Nationally recognized contract manufacturing, regulatory & quality management firms are supporting company growth.

 

Our fundraising

Series A investment was successfully over-subscribed with a syndicate of experienced investors. The Company closed the anticipated $8m round at $9M. Use of proceeds are to support the completion of development of XaTek’s first commercial product, including a large multi-center pivotal trial and filing for FDA clearance in two different markets.